Urteste S.A. (URT.WA)
PLN 92.8
(-1.28%)
PLN 92.8
(-1.28%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -512 Thousand PLN | 81.95% |
| 2022 | -2.83 Million PLN | 63.74% |
| 2021 | -7.82 Million PLN | -1730.59% |
| 2020 | -427.34 Thousand PLN | -146.65% |
| 2019 | -173.26 Thousand PLN | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -1.69 Million PLN | -231.45% |
| 2024 Q2 | -122 Thousand PLN | 92.81% |
| 2023 Q1 | -1.59 Million PLN | 43.88% |
| 2023 Q4 | -512 Thousand PLN | 17.29% |
| 2023 Q3 | -619 Thousand PLN | 97.82% |
| 2023 Q2 | -28.38 Million PLN | -1682.85% |
| 2023 FY | -512 Thousand PLN | 81.95% |
| 2022 Q1 | 7 Million PLN | 182.13% |
| 2022 Q4 | -2.83 Million PLN | 18.5% |
| 2022 Q3 | -3.48 Million PLN | 27.57% |
| 2022 Q2 | -4.8 Million PLN | -168.58% |
| 2022 FY | -2.83 Million PLN | 63.74% |
| 2021 Q1 | 391.14 Thousand PLN | 0.0% |
| 2021 FY | -7.82 Million PLN | -1730.59% |
| 2021 Q4 | -8.53 Million PLN | -185.14% |
| 2021 Q3 | 10.02 Million PLN | 697.21% |
| 2021 Q2 | -1.67 Million PLN | -529.03% |
| 2020 FY | -427.34 Thousand PLN | -146.65% |
| 2019 FY | -173.26 Thousand PLN | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bioceltix S.A. | -9.13 Million PLN | 94.395% |
| BIOTON S.A. | 64.81 Million PLN | 100.79% |
| Captor Therapeutics Spolka Akcyjna | -71.92 Million PLN | 99.288% |
| Mabion S.A. | -11.98 Million PLN | 95.729% |
| Molecure S.A. | -56.84 Million PLN | 99.099% |
| NanoGroup S.A. | -537.61 Thousand PLN | 4.764% |
| Pharmena S.A. | -22.05 Million PLN | 97.679% |
| Poltreg S.A. | -57.75 Million PLN | 99.114% |
| Pure Biologics Spólka Akcyjna | 9.33 Million PLN | 105.486% |
| Ryvu Therapeutics S.A. | -57.03 Million PLN | 99.102% |
| Synthaverse S.A. | 67.86 Million PLN | 100.754% |